What is it about?

Patients that have lung cancer without lymph node involvement but who cannot have surgery because of other limitations can be treated with stereotactic ablative radiotherapy (SABR). However, if there is lymph node involvement, SABR will not work. It is therefore useful for physicians to be able to estimate the probability that lung cancer patients have lymph node involvement. This study develops a mathematical model to predict the probability that a given patient has lymph node involvement. The model uses four variables to make this prediction: type of cancer present (histology), age of the patient, presence of lymph node abnormalities on CT and PET imaging, and location of the tumor. Four hospitals tested the model. The model effectively discriminated between patients that had no lymph node involvement (N0), early nodal involvement (N1), and regional lymph node involvement (N2 or N3). The predicted probability of disease was similar to the observed probability of disease in different patient groups.

Featured Image

Read the Original

This page is a summary of: A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER, American Review of Respiratory Disease, January 2020, American Thoracic Society,
DOI: 10.1164/rccm.201904-0831oc.
You can read the full text:

Read

Contributors

Be the first to contribute to this page